Revenue fell 12.26% YoY to ¥4.04 billion, but net profit jumped 26.03% to ¥669 million, driven by improved margins and strong cash flow. Heart/cerebrovascular and respiratory products remain core, while R&D investment and new product launches support future growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.